<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Larsson M</submitter><funding>American Heart Association</funding><funding>Fondation Leducq</funding><funding>Foundation for the National Institutes of Health</funding><funding>NHLBI NIH HHS</funding><pagination>1893-1902</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5580902</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>58(9)</volume><pubmed_abstract>apoC-III is often assumed to retard the intravascular processing of triglyceride-rich lipoproteins (TRLs) by inhibiting LPL, but that view is based largely on studies of free LPL. We now recognize that intravascular LPL is neither free nor loosely bound, but instead is tightly bound to glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) on endothelial cells. Here, we revisited the effects of apoC-III on LPL, focusing on apoC-III's capacity to affect the activity of GPIHBP1-bound LPL. We found that TRLs from &lt;i>APOC3&lt;/i> transgenic mice bound normally to GPIHBP1-bound LPL on cultured cells in vitro and to heart capillaries in vivo. However, the triglycerides in apoC-III-enriched TRLs were hydrolyzed more slowly by free LPL, and the inhibitory effect of apoC-III on triglyce</pubmed_abstract><journal>Journal of lipid research</journal><pubmed_title>Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.</pubmed_title><pmcid>PMC5580902</pmcid><funding_grant_id>15POST22960055</funding_grant_id><funding_grant_id>P01 HL090553</funding_grant_id><funding_grant_id>12CVD04</funding_grant_id><pubmed_authors>Fong LG</pubmed_authors><pubmed_authors>Larsson M</pubmed_authors><pubmed_authors>Heizer PJ</pubmed_authors><pubmed_authors>Jung RS</pubmed_authors><pubmed_authors>Young SG</pubmed_authors><pubmed_authors>Beigneux AP</pubmed_authors><pubmed_authors>Allan CM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.</name><description>apoC-III is often assumed to retard the intravascular processing of triglyceride-rich lipoproteins (TRLs) by inhibiting LPL, but that view is based largely on studies of free LPL. We now recognize that intravascular LPL is neither free nor loosely bound, but instead is tightly bound to glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) on endothelial cells. Here, we revisited the effects of apoC-III on LPL, focusing on apoC-III's capacity to affect the activity of GPIHBP1-bound LPL. We found that TRLs from &lt;i>APOC3&lt;/i> transgenic mice bound normally to GPIHBP1-bound LPL on cultured cells in vitro and to heart capillaries in vivo. However, the triglycerides in apoC-III-enriched TRLs were hydrolyzed more slowly by free LPL, and the inhibitory effect of apoC-III on triglyce</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Sep</publication><modification>2025-04-19T22:15:53.133Z</modification><creation>2019-03-26T23:53:08Z</creation></dates><accession>S-EPMC5580902</accession><cross_references><pubmed>28694296</pubmed><doi>10.1194/jlr.M078220</doi><doi>10.1194/jlr.m078220</doi></cross_references></HashMap>